Company Filing History:
1 out of 2,405 
1 out of 40 
Years Active: 2017
Title: Helen Juteau: Innovator in HIV Research
Introduction
Helen Juteau is a notable inventor based in Ville St-Laurent, Canada. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of HIV protease inhibitors. Her work has the potential to impact the treatment and prevention of HIV and AIDS.
Latest Patents
Helen Juteau holds a patent for her invention related to HIV protease inhibitors. The patent focuses on 5-heteroarylmorpholine derivatives and their application in inhibiting HIV protease. This innovation aims to inhibit HIV replication, provide prophylaxis against HIV infection, and treat existing infections. The compounds can also be used in pharmaceutical compositions, potentially in combination with other antivirals, immunomodulators, antibiotics, or vaccines.
Career Highlights
Throughout her career, Helen has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck Canada Inc. Her experience in these organizations has allowed her to contribute to significant advancements in HIV research and treatment.
Collaborations
Helen has collaborated with esteemed colleagues such as John A. McCauley and Christian Beaulieu. These partnerships have further enriched her research and development efforts in the field of HIV treatment.
Conclusion
Helen Juteau's innovative work in the development of HIV protease inhibitors showcases her dedication to advancing medical science. Her contributions have the potential to improve the lives of many individuals affected by HIV and AIDS.